Mesa Laboratories, Inc. — FY2024 Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2024. The provided filing is not a 2022 Q4 filing; it is the FY2024 annual report, filed June 28, 2024. Mesa develops life sciences tools and quality-control solutions for pharmaceutical, healthcare, medical-device and regulated industrial markets. Its four reportable segments are Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development and Calibration Solutions.
Key financial metrics
| Metric | FY2024 | FY2023 | Change |
|---|---|---|---|
| Revenue | $216.2 million | $219.1 million | Down 1% |
| Gross profit | $133.3 million | $133.7 million | Approximately flat |
| Gross margin | 61.6% | 61.0% | Up approximately 0.6 percentage points |
| Operating expenses | $405.3 million | $130.4 million | Increase driven by impairment |
| Operating income | $(272.1) million | $3.3 million | Material decline |
| Net income | $(254.2) million | $0.9 million | Material decline |
| Basic and diluted EPS | $(47.20) | $0.17 | Material decline |
| Adjusted operating income | $46.0 million | $49.0 million | Down 6% |
| Cash flow from operations | $44.1 million | $28.0 million | Up 58% |
| Capital expenditures | $2.6 million | $4.5 million | Down 44% |
Dollar amounts are presented in millions unless otherwise stated. Adjusted operating income is a non-GAAP measure excluding amortization, depreciation, stock-based compensation and impairment losses.
Segment performance
| Segment | FY2024 revenue | Year-over-year change | Gross margin |
|---|---|---|---|
| Sterilization and Disinfection Control | $75.1 million | Up 16% | 71% |
| Clinical Genomics | $52.6 million | Down 16% | 51% |
| Biopharmaceutical Development | $40.7 million | Down 14% | 62% |
| Calibration Solutions | $47.8 million | Up 7% | 58% |
Material changes versus the prior comparable period
- Revenue declined modestly overall, as growth in Sterilization and Disinfection Control and Calibration Solutions was more than offset by declines in Clinical Genomics and Biopharmaceutical Development.
- Clinical Genomics was affected by the loss of Sema4, weaker Chinese demand and reduced customer purchases of capital equipment. Management expects Clinical Genomics revenue to remain approximately flat in FY2025 while a new strategy is implemented.
- Biopharmaceutical Development experienced lower instrument demand as biopharmaceutical customers reduced discretionary capital spending. Consumables and services revenue nevertheless increased 10%.
- Calibration Solutions benefited from abating supply-chain constraints and the fulfillment of previously delayed orders.
- Sterilization and Disinfection Control included $9.3 million of revenue from the GKE acquisition. Excluding GKE, segment revenue increased approximately 2%.
- Fiscal 2024 included $274.5 million of non-cash impairment losses: $156.9 million for goodwill and $117.6 million for finite-lived intangible assets, primarily in Clinical Genomics and Biopharmaceutical Development.
- Backlog declined to approximately $25.5 million at March 31, 2024 from $38.1 million at March 31, 2023, primarily because of lower Clinical Genomics orders and the fulfillment of Calibration Solutions backlog.
Cash, debt and liquidity
- Cash and cash equivalents were $28.2 million at March 31, 2024, compared with $32.9 million a year earlier. Working capital was $65.0 million, down from $75.6 million.
- Debt at year-end included $172.5 million principal amount of 1.375% convertible notes due August 15, 2025 and $50.5 million outstanding under the Credit Facility.
- The GKE acquisition cost $87.2 million, funded with cash and $71.0 million of Credit Facility borrowings. Approximately $9.3 million was held back for potential indemnification claims.
- In April 2024, Mesa amended its Credit Facility, extending maturity to April 2029 and adding a $75.0 million term loan. It used the term-loan proceeds to repurchase $75.0 million principal amount of the 2025 Notes for approximately $71.4 million, including accrued interest.
- Mesa expects to settle the remaining $97.5 million principal amount of the 2025 Notes in cash at maturity using operating cash flow and revolving borrowings. Management states that operating cash flow should fund scheduled debt payments, interest, dividends and anticipated capital expenditures.
- The company paid quarterly dividends of $0.16 per share throughout FY2024 and declared another $0.16 per share quarterly dividend in April 2024.
Outlook, commentary, risks and unusual items
- Management expects approximately $4.0 million of incremental FY2025 cost savings from workforce reductions and other initiatives, although performance-based compensation could offset a substantial portion.
- Management expects FY2025 non-cash amortization expense to decrease by approximately $3.7 million in cost of revenues and $6.8 million in operating expenses in Clinical Genomics following the impairment charges.
- Further impairment risk is elevated in Clinical Genomics and Biopharmaceutical Development. Certain impaired reporting units had effectively no excess fair value over carrying value at the January 1, 2024 testing date.
- The company is pursuing FDA 510(k) clearance for certain GKE products in the United States, which could expand GKE’s addressable market but remains subject to regulatory uncertainty.
- Macroeconomic risks include elevated interest rates, reduced capital spending, economic weakness in China, foreign-currency volatility, inflation, geopolitical disruptions and supply-chain constraints.
- The FDA’s April 2024 changes affecting enforcement discretion for laboratory-developed tests may affect certain future U.S. Clinical Genomics revenue; Mesa was still assessing the impact.
- Management identified three material weaknesses in internal control over financial reporting involving review of complex transactions, useful-life determinations for acquired intangible assets and ERP access/change-management controls. Management and the auditor concluded that internal control was not effective as of March 31, 2024, although the financial statements received an unqualified audit opinion.
- Mesa reported no legal proceeding that management believes would materially adversely affect its consolidated financial position, results of operations or cash flows.
Important facts for investors to verify
- Whether operating performance in Clinical Genomics and Biopharmaceutical Development stabilizes and whether additional impairment charges occur.
- Execution of the new Clinical Genomics strategy, including the effect of the workforce reduction and expected FY2025 revenue trajectory.
- GKE integration, achievement of expected synergies and the timing and outcome of U.S. 510(k) clearances.
- Ability to generate sufficient cash to repay or refinance the remaining $97.5 million of 2025 Notes at maturity.
- Compliance with Credit Facility leverage and fixed-charge coverage covenants after the April 2024 refinancing.
- Remediation of the three material weaknesses and the auditor’s assessment of internal control in subsequent filings.
- Impact of FDA laboratory-developed-test regulation, China-related demand weakness, foreign exchange and elevated interest rates.
- Whether backlog continues to decline and whether the reported $25.5 million backlog converts to revenue as expected.